Our New Agents Committee (NAC) members have expertise in clinical trials and other aspects of drug development. NAC-approved novel agents in development have included molecularly targeted small molecules, antibodies, vaccines, immunotherapy and cell therapy.
Learn about the Centre for Drug DevelopmentThis scheme supports researchers from academia and industry to develop new cancer treatments from preclinical development through to early phase patient trials.
The NAC is interested in proposals for scientifically-driven trials of novel unregistered anti-cancer agents including:
preclinical development prior to a clinical trial
phase 1 trials, including first-in-human and first-in-class
combination trials of unregistered and registered agents
early phase 2 hypothesis-testing trials
Proposals undergo external, international peer review and are judged on the basis of:
scientific rationale and importance
uniqueness/novelty of the target or agent
clinical direction and unmet medical need
quality of supporting data in relevant models
Read about the committee's terms of reference(PDF, 202 KB)
Professor Pat LoRusso, Yale Cancer Center
Professor Mark Cragg - University of Southampton
Dr Fieke Froeling - University of Glasgow
Professor Linda Hakes - Independent, Germany
Professor Aslaug Helland - University of Oslo
Dr Sheeba Irshad - Kings College London
Dr Allan Jordan - Sygnature
Bo Kara - Mereo BioPharma
Dr Elaine Kilgour- Redx Pharma
Dr Rebecca Kristeleit - Guy's & St Thomas NHS Foundation Trust
Professor Kjetil Tasken - University of Oslo
Professor Fiona Thistlethwaite - University of Manchester
Dr Astrid van der Veldt - Erasmus MC, Rotterdam
Professor Bart Vanhaesebroeck - University College London
Professor Steve Wedge - University of Newcastle
Professor Tim Yap - MD Anderson, University of Texas
Our strategy shapes how we'll discover more about how cancer develops and progresses to unlock new and better ways to prevent, detect and treat it.
Approved Drug Development Projects are sponsored and managed by our Centre for Drug Development (CDD). CDD partners with academics, biotech, and pharma to deliver early-phase clinical trials.
